Keresés eredménye

Típusa:

összetett keresés

Keresési paraméterek:

David S. Siegel | szakcikk |

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

LBA-6 Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03

Szerző: Saad Z. Usmani, MD, MBBS¹ Hang Quach, MD² María-Victoria Mateos³ Ola Landgren, MD, PhD⁴ Xavier Leleu, MD, PhD⁵ David S. Siegel⁶ Katja Weisel⁷ Hui Yang⁸ Zandra K. Klippel, MD⁹ Anita Zahlten-Kumeli¹⁰ Meletios A. Dimopoulos, MD¹¹
¹Atrium Health, Charlotte, NC
²St. Vincent's Hospital, Melbourne, Australia
³University Hospital Salamanca/IBSAL, Salamanca, Spain
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Hopital Claude Huriez, Lille, France
⁶John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
⁷Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
⁸Amgen, Inc., Thousand Oaks, CA
⁹Amgen, Inc., Thousand Oaks, CA
¹⁰Amgen, Inc., Thousand Oaks, CA
¹¹National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Introduction: The use of lenalidomide (LEN) and bortezomib (BTZ) in newly diagnosed multiple myeloma (MM) patients (pts), along with continuous or maintenance therapy paradigm have improved survival outcomes. However, many pts progress while on these agents or discontinue them due to toxicity. There is a need for novel, efficacious, and tolerable regimens that can treat MM pts who are exposed or refractory to LEN or BTZ. The proteasome inhibitor ...

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!